股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢友芝友生物製藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 3. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | 於香港聯交所上市 (註1) | 否 | | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市外資股 | | | 第 1 頁 共 11 頁 v 1.1.1 FF301 FF301 | | 法定/註冊股份數目 | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 6,869,744 RMB | 1 RMB | | 6,869,744 | | 增加 / 減少 (-) | | 0 | RMB | | 0 | | 本月底結存 | | 6,869,744 RMB | 1 RMB ...

Group 1 - The core viewpoint of the article highlights that *ST Huifeng (002496) has experienced revenue growth but significant profit decline in its 2025 mid-year report, indicating a challenging financial situation [1] - The company's total operating revenue reached 157 million yuan, a year-on-year increase of 42.6%, while the net profit attributable to shareholders was 11.47 million yuan, a year-on-year decrease of 67.02% [1] - The gross profit margin was reported at 10.01%, down 65.83% year-on-year, and the net profit margin was 5.58%, down 82.21% year-on-year, reflecting deteriorating profitability [1] Group 2 - The company reported a significant increase in sales expenses, management expenses, and financial expenses totaling 57.27 million yuan, which accounted for 36.47% of revenue, a decrease of 42.54% year-on-year [1] - The earnings per share (EPS) decreased to 0.01 yuan, down 67.1% year-on-year, indicating a decline in shareholder returns [1] - The company's historical financial performance has been poor, with a median return on invested capital (ROIC) of -8.51% over the past decade, and a particularly low ROIC of -23.34% in 2023 [3]

Group 1 - The core point of the article is that *ST Huifeng (002496.SZ) released its semi-annual report for 2025, indicating the current status of institutional ownership [1] - As of August 26, 2025, there is one institutional investor holding shares in *ST Huifeng, with a total holding of 30.5953 million shares, representing 2.03% of the total share capital [1] - The institutional investor includes Jiangsu Huifeng Biological Agriculture Co., Ltd. - Phase I Employee Stock Ownership Plan, maintaining the same holding percentage [1]

智通财经APP讯，友芝友生物-B(02496)发布截至2025年6月30日止六个月业绩，收入3718.7万元(人民 币，下同);净亏损5883.4万元，同比收窄25%;每股基本亏损0.30元。 于报告期内，收入包括：许可费收入及研发服务收入。许可费收入主要是公司与正大天晴签订了一项许 可合作协定。截至2025年6月30日止六个月，集团就授予许可使用权以实现发展里程碑确认收入470万 元。 研发服务收入主要是依据公司与正大天晴签订的许可合作协定，公司为其提供委托研发服务。在截至 2025年6月30日止六个月，公司根据满足履约义务所付出的努力或投入与预计为满足该履约义务所需的 总投入之间的相对比例按进度确认了3250万元的研发服务收入。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 WUHAN YZY BIOPHARMA CO., LTD. 武漢友芝友生物製藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 截至2025年6月30日止六個月的中期業績公告 武漢友芝友生物製藥股份有限公司（「本公司」，連同其附屬公司，「本集團」）的董 事（「董事」）會（「董事會」）欣然宣佈本集團截至2025年6月30日止六個月（「報告 期」）的未經審計綜合中期業績，連同截至2024年6月30日止六個月（「同期」）的比 較數字。 於本公告中，「我們」及「我們的」指本公司及（如文義另有所指）本集團。本公告 所載若干金額及百分比數字已進行約整或約整至小數點後一位或兩位（如適用）。 任何表格、圖表或其他地方所列總額及數額總和的任何差異乃由於四捨五入所致。 1 財務摘要 | | 截至6月30日止六個月 | | | --- | --- | --- | | | 2025年 | 202 ...

格隆汇8月14日丨友芝友生物-B(02496.HK)公布，公司将于2025年8月26日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 WUHAN YZY BIOPHARMA CO., LTD. 武漢友芝友生物製藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496) 董事會會議召開日期 武漢友芝友生物製藥股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於 2025年8月26日（星期二）舉行董事會會議，藉以（其中包括）考慮及批准本公司及 其附屬公司截至2025年6月30日止六個月的中期業績及其發佈，以及處理其他事 項。 承董事會命 武漢友芝友生物製藥股份有限公司 董事長、執行董事兼首席執行官 Zhou Pengfei博士 中國武漢，2025年8月14日 於本公告日期，董事會包括執行董事Zhou Pengfei博士及溫植成先生；非執行董 事袁謙博士、周宏峰博士、龐振海先生、惠希武博士及謝守武先生；及獨立非執 行董事程斌博士、付黎黎女士、鄧躍臻博士及陳斌博士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢友芝友生物製藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 FF301 | | 法定/註冊股份數目 | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 6,869,744 RMB | 1 RMB | | 6,869,744 | | 增加 / 減少 (-) | | 0 | RMB | | 0 | | 本月底結存 | | 6,869,744 RMB | 1 RMB | | 6,869,744 | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02496 | 說明 | ...

金融界消息 截至2025年7月29日收盘，*ST辉丰（002496）报收于1.67元，下跌3.47%，换手率2.46%， 成交量29.00万手，成交金额4863.53万元。 通过天眼查大数据分析，江苏辉丰生物农业股份有限公司共对外投资了32家企业，参与招投标项目190 次，知识产权方面有商标信息365条，专利信息136条，此外企业还拥有行政许可223个。 资金流向方面，今日主力资金净流出1431.74万元，占比成交额29.44%。其中，超大单净流出555.52万 元、占成交额11.42%，大单净流出876.23万元、占成交额18.02%，中单净流出流入754.28万元、占成交 额15.51%，小单净流入677.46万元、占成交额13.93%。 来源：金融界 *ST辉丰最新一期业绩显示，截至2025一季报，公司营业总收入7402.32万元、同比增长29.37%，归属净 利润1565.82万元，同比减少67.63%，扣非净利润1172.82万元，同比增长231.40%，流动比率0.405、速 动比率0.334、资产负债率44.94%。 天眼查商业履历信息显示，江苏辉丰生物农业股份有限公司，成立于1989年，位于盐 ...

Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching RMB 1.2 billion for the fiscal year ending December 31, 2023[6]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues to reach RMB 1.32 billion[6]. - For the fiscal year ending December 31, 2024, the company reported a revenue of RMB 107.813 million, with a gross profit of RMB 85.069 million[24]. - Total revenue for the year ended December 31, 2024, reached RMB 107.8 million[47]. - License fee income for the year ended December 31, 2024, was RMB 82.8 million, accounting for 76.8% of total revenue[45]. - R&D service income for the same period was RMB 25.0 million, representing 23.2% of total revenue[46]. - The company recorded a pre-tax loss of RMB 97.599 million for 2024, an improvement from a loss of RMB 191.702 million in 2023[24]. - Total loss and comprehensive expenses for the reporting period were RMB 97.6 million, a decrease of RMB 94.1 million compared to RMB 191.7 million in the previous year, attributed to increased revenue and reduced listing expenses[61]. Research and Development - Investment in R&D increased by 25%, amounting to RMB 300 million, focusing on new product development and technology advancements[6]. - Research and development expenses increased to RMB 164.986 million in 2024, compared to RMB 155.054 million in 2023, indicating a focus on innovation[24]. - R&D spending on technical service fees accounted for 69.8% of total R&D expenses, increasing from 61.6% in the previous year[55]. - The core product M701 is currently in Phase III clinical trials for treating malignant ascites (MA) and has shown promising preliminary efficacy and safety signals[33]. - M701 is also undergoing Phase Ib/II clinical trials for malignant pleural effusion (MPE), with 24 patients recruited in the Ib phase, demonstrating initial efficacy in controlling MPE in NSCLC patients[33]. - The company plans to submit a Biologics License Application (BLA) for M701 in 2025, following successful clinical trial milestones[28]. - The company has established long-term strategic partnerships in early-stage research with academic institutions, research organizations, and CSOs, focusing on target identification and preclinical drug development[21]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2025[6]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[85]. - Market expansion efforts include entering three new international markets, aiming for a 10% increase in market share by the end of the next fiscal year[86]. - The company is launching a new dual-specific antibody product, anticipated to generate RMB 500 million in revenue within the first year of launch[6]. Corporate Governance - The company has established a corporate governance framework in accordance with the corporate governance code outlined in the listing rules[115]. - The board promotes a corporate culture that aligns with the company's mission, values, and strategies[114]. - The company has adopted the standard code of conduct as per the listing rules, ensuring compliance by all directors and relevant employees regarding insider trading[118]. - The board of directors is composed of a balanced mix of executive and non-executive directors, ensuring strong independent judgment[119]. - The company is committed to maintaining high standards of corporate governance through the appointment of qualified and experienced directors and supervisors[92][100]. Shareholder Communication - The company emphasizes effective communication with shareholders to strengthen investor relations and understanding of business performance and strategies[190]. - The company has established multiple channels for ongoing dialogue with shareholders, including company communications and announcements[192]. - The company has a shareholder communication policy to ensure timely and equal access to comprehensive information regarding financial performance and strategic goals[191]. - The company will hold investor/analyst briefings, roadshows, and other events to enhance communication with investors[200]. Strategic Acquisitions - A strategic acquisition of a local biotech firm was announced, expected to enhance the company's product pipeline and capabilities[6]. - The company has completed two strategic acquisitions in the past year, enhancing its product portfolio and increasing its competitive edge[89]. Operational Efficiency - The gross margin improved to 60%, up from 55% in the previous year, reflecting operational efficiencies[6]. - The company aims to reduce operational costs by 10% through process optimization initiatives[6]. - The management team emphasizes a focus on sustainable practices, aiming to reduce operational costs by 5% through efficiency improvements[87]. Management Team - The company has a strong management team with diverse backgrounds in finance, clinical medicine, and auditing, enhancing its operational oversight[95][98]. - The company has a strategic focus on expanding its management team with experienced professionals to enhance governance and oversight[94][96]. - The management team includes professionals with advanced degrees from prestigious institutions, such as Oxford University and Huazhong University of Science and Technology[95][98]. Clinical Trials - The Y400 project has successfully entered Phase II clinical trials in China, with ongoing collaborative development efforts with Kangzhe Pharmaceutical for overseas markets[21]. - Y101D completed Phase I clinical trial for metastatic or locally advanced solid tumors in September 2024[35]. - Y332 initiated Phase I clinical trial for metastatic or locally advanced solid tumors in October 2023, with 18 subjects enrolled by February 2025[36]. - Y400 advanced to Phase II multi-center clinical trial in China for age-related macular degeneration, showing good safety and efficacy in Phase I[37]. Financial Management - As of December 31, 2024, cash and cash equivalents decreased to RMB 126.3 million from RMB 196.7 million at the end of 2023, primarily due to increased R&D investments[62]. - Current assets totaled RMB 221.3 million, including cash and cash equivalents of RMB 126.3 million and trade and other receivables of RMB 90.7 million[62]. - Current liabilities amounted to RMB 186.1 million, with bank borrowings of RMB 75.8 million and trade and other payables of RMB 49.4 million[62]. - The company has implemented internal control policies for capital management, allowing investments only in structured deposits and principal-protected financial products issued by major commercial banks in China[65].